 | • レポートコード：QFJ1-5890 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、非ホジキンリンパ腫治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫療法、標的療法、化学療法、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・非ホジキンリンパ腫治療の市場動向 ・企業の競争状況、市場シェア ・非ホジキンリンパ腫治療の種類別市場規模と予測2016-2027（免疫療法、標的療法、化学療法、その他） ・非ホジキンリンパ腫治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局、その他） ・非ホジキンリンパ腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・非ホジキンリンパ腫治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・非ホジキンリンパ腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非ホジキンリンパ腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・非ホジキンリンパ腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Takeda Pharmaceutical Company Limited、AstraZeneca、Bayer、Novartis AG、Gilead Sciences、Spectrum Pharmaceuticals、Teva Pharmaceutical Industries Ltd.、Bristol Myers Squibb Company、Janssen Pharmaceuticals、Roche、CELGENE CORPORATION (Bristol Myers Squibb Company)、Merck & Co., Inc.、Kyowa Kirin Co., Ltd.、AbbVie、Sanofi） ・結論 |
Non-Hodgkin’s lymphomas are one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed.
Market Analysis and Insights: Global Non-Hodgkin Lymphoma Treatment Market
The global Non-Hodgkin Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Hodgkin Lymphoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Hodgkin Lymphoma Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Hodgkin Lymphoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Hodgkin Lymphoma Treatment market.
Global Non-Hodgkin Lymphoma Treatment Scope and Market Size
Non-Hodgkin Lymphoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Hodgkin Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Immunotherapy
Targeted Therapy
Chemotherapy
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Takeda Pharmaceutical Company Limited
AstraZeneca
Bayer
Novartis AG
Gilead Sciences
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
Janssen Pharmaceuticals
Roche
CELGENE CORPORATION (Bristol Myers Squibb Company)
Merck & Co., Inc.
Kyowa Kirin Co., Ltd.
AbbVie
Sanofi
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2016-2027)
2.2 Non-Hodgkin Lymphoma Treatment Growth Trends by Regions
2.2.1 Non-Hodgkin Lymphoma Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Non-Hodgkin Lymphoma Treatment Industry Dynamic
2.3.1 Non-Hodgkin Lymphoma Treatment Market Trends
2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue
3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2016-2021)
3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Treatment Revenue
3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2020
3.5 Non-Hodgkin Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Non-Hodgkin Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Hodgkin Lymphoma Treatment Breakdown Data by Type
4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2016-2021)
4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2022-2027)
5 Non-Hodgkin Lymphoma Treatment Breakdown Data by Application
5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2016-2021)
5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
6.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type
6.2.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
6.2.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
6.2.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Application
6.3.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
6.3.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
6.3.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country
6.4.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
6.4.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
7.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type
7.2.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
7.2.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
7.2.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application
7.3.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
7.3.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
7.3.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country
7.4.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
7.4.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type
8.2.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application
8.3.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region
8.4.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type
9.2.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application
9.3.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country
9.4.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2016-2027)
10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type
10.2.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application
10.3.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country
10.4.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Takeda Pharmaceutical Company Limited
11.1.1 Takeda Pharmaceutical Company Limited Company Details
11.1.2 Takeda Pharmaceutical Company Limited Business Overview
11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.1.5 Takeda Pharmaceutical Company Limited Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.3.5 Bayer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Details
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.5.5 Gilead Sciences Recent Development
11.6 Spectrum Pharmaceuticals
11.6.1 Spectrum Pharmaceuticals Company Details
11.6.2 Spectrum Pharmaceuticals Business Overview
11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.6.5 Spectrum Pharmaceuticals Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Details
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.8 Bristol Myers Squibb Company
11.8.1 Bristol Myers Squibb Company Company Details
11.8.2 Bristol Myers Squibb Company Business Overview
11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.8.5 Bristol Myers Squibb Company Recent Development
11.9 Janssen Pharmaceuticals
11.9.1 Janssen Pharmaceuticals Company Details
11.9.2 Janssen Pharmaceuticals Business Overview
11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.9.5 Janssen Pharmaceuticals Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.10.5 Roche Recent Development
11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
11.12 Merck & Co., Inc.
11.12.1 Merck & Co., Inc. Company Details
11.12.2 Merck & Co., Inc. Business Overview
11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.12.5 Merck & Co., Inc. Recent Development
11.13 Kyowa Kirin Co., Ltd.
11.13.1 Kyowa Kirin Co., Ltd. Company Details
11.13.2 Kyowa Kirin Co., Ltd. Business Overview
11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.13.5 Kyowa Kirin Co., Ltd. Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.14.5 AbbVie Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Details
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
11.15.5 Sanofi Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Others
Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2016-2021)
Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2022-2027)
Table 12. Non-Hodgkin Lymphoma Treatment Market Trends
Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers
Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges
Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints
Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2016-2021)
Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2020)
Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
Table 23. Date of Enter into Non-Hodgkin Lymphoma Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Takeda Pharmaceutical Company Limited Company Details
Table 64. Takeda Pharmaceutical Company Limited Business Overview
Table 65. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product
Table 66. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 67. Takeda Pharmaceutical Company Limited Recent Development
Table 68. AstraZeneca Company Details
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Non-Hodgkin Lymphoma Treatment Product
Table 71. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Bayer Company Details
Table 74. Bayer Business Overview
Table 75. Bayer Non-Hodgkin Lymphoma Treatment Product
Table 76. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Novartis AG Company Details
Table 79. Novartis AG Business Overview
Table 80. Novartis AG Non-Hodgkin Lymphoma Treatment Product
Table 81. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 82. Novartis AG Recent Development
Table 83. Gilead Sciences Company Details
Table 84. Gilead Sciences Business Overview
Table 85. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product
Table 86. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 87. Gilead Sciences Recent Development
Table 88. Spectrum Pharmaceuticals Company Details
Table 89. Spectrum Pharmaceuticals Business Overview
Table 90. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 91. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 92. Spectrum Pharmaceuticals Recent Development
Table 93. Teva Pharmaceutical Industries Ltd. Company Details
Table 94. Teva Pharmaceutical Industries Ltd. Business Overview
Table 95. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 96. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Ltd. Recent Development
Table 98. Bristol Myers Squibb Company Company Details
Table 99. Bristol Myers Squibb Company Business Overview
Table 100. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 101. Bristol Myers Squibb Company Recent Development
Table 102. Janssen Pharmaceuticals Company Details
Table 103. Janssen Pharmaceuticals Business Overview
Table 104. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 105. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 106. Janssen Pharmaceuticals Recent Development
Table 107. Roche Company Details
Table 108. Roche Business Overview
Table 109. Roche Non-Hodgkin Lymphoma Treatment Product
Table 110. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 111. Roche Recent Development
Table 112. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
Table 113. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
Table 114. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product
Table 115. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 116. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
Table 117. Merck & Co., Inc. Company Details
Table 118. Merck & Co., Inc. Business Overview
Table 119. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product
Table 120. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 121. Merck & Co., Inc. Recent Development
Table 122. Kyowa Kirin Co., Ltd. Company Details
Table 123. Kyowa Kirin Co., Ltd. Business Overview
Table 124. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 125. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 126. Kyowa Kirin Co., Ltd. Recent Development
Table 127. AbbVie Company Details
Table 128. AbbVie Business Overview
Table 129. AbbVie Non-Hodgkin Lymphoma Treatment Product
Table 130. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 131. AbbVie Recent Development
Table 132. Sanofi Company Details
Table 133. Sanofi Business Overview
Table 134. Sanofi Non-Hodgkin Lymphoma Treatment Product
Table 135. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2016-2021) & (US$ Million)
Table 136. Sanofi Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2020 VS 2027
Figure 2. Immunotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Others Features
Figure 6. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Others Case Studies
Figure 11. Non-Hodgkin Lymphoma Treatment Report Years Considered
Figure 12. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Share by Regions (2022-2027)
Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2020
Figure 17. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2020
Figure 19. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
Figure 23. North America Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
Figure 24. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
Figure 25. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
Figure 29. Europe Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
Figure 30. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
Figure 31. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2016-2027)
Figure 41. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 61. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 63. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 64. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 65. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 67. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 68. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 69. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 70. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 71. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 72. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 73. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 74. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の非ホジキンリンパ腫＆慢性リンパ腫治療市場規模・現状・予測（2021年-2027年） Non-Hodgkins Lymphoma also known as NHL is a heterogeneous and complex group of disorders that are characterized by clonal proliferation of lymphocytes at multiple stages of maturation. There are approximately 30 types of NHLs with varying pathological, clinical, and genetic features. Chronic Lympho…- 世界のB細胞非ホジキンリンパ腫（NHL）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment Market The global B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy…
- ホジキンリンパ腫治療のグローバル市場調査 2019年 The global Hodgkin Lymphoma Treatment market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Hodgkin Lymphoma Treatment volume and value at global level, regional level and company level. From a global per…
- 世界の皮膚B細胞リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Cutaneous B-Cell Lymphoma Treatment Market The global Cutaneous B-Cell Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and hig…
- 世界の辺縁帯リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Marginal Zone Lymphoma Treatment Market The global Marginal Zone Lymphoma Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data…